# A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

> **NCT06716424** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 105 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** iGlarLixi (insulin glargine/lixisenatide)

## Key facts

- **NCT ID:** NCT06716424
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2026-06-26
- **Final completion:** 2026-06-26
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716424, "A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06716424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*